Processing

Please wait...

Settings

Settings

1. WO1991000349 - CYTOKINE SYNTHESIS INHIBITORY FACTOR, ANTAGONISTS THEREOF, AND METHODS OF USING SAME

Publication Number WO/1991/000349
Publication Date 10.01.1991
International Application No. PCT/US1990/003554
International Filing Date 28.06.1990
Chapter 2 Demand Filed 07.01.1991
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/54 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins (IL)
C07K 16/24 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/5428
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
52Cytokines; Lymphokines; Interferons
54Interleukins [IL]
5428IL-10
C07K 16/244
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
244Interleukins [IL]
Y02A 50/41
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
38Medical treatment of vector-borne diseases characterised by the agent
408the vector-borne disease being caused by a protozoa
409of the genus Leishmania i.e. Leishmaniasis, Sand-fly fever, phlebotomus fever, kala-azar, black fever or Dumdum fever
41the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
Applicants
  • SCHERING CORPORATION [US/US]; 2000 Galloping Hill Road Kenilworth, NJ 07033, US
Inventors
  • MOSMANN, Timothy, R.; CA
  • MOORE, Kevin, W.; US
  • BOND, Martha, W.; US
  • VIEIRA, Paulo, J., M.; US
Agents
  • BLASDALE, John, H., C.; Schering-Plough Corporation One Giralda Farms Madison, NJ 07940-1000, US
Priority Data
372,66728.06.1989US
453,95120.12.1989US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CYTOKINE SYNTHESIS INHIBITORY FACTOR, ANTAGONISTS THEREOF, AND METHODS OF USING SAME
(FR) FACTEUR INHIBITEUR DE LA SYNTHESE DE CYTOKINES, SES ANTAGONISTES, AINSI QUE SES PROCEDES D'UTILISATION
Abstract
(EN)
Mammalian genes and proteins, designated cytokine synthesis inhibitory factors (CSIFs), are provided which are capable of inhibiting the synthesis of cytokines associated with delayed type hypersensitivity responses, and which, together with antagonists, are useful in treating diseases associated with cytokine imbalances, such as leishmaniasis and other parasitic infections, and certain immune disorders including MHC associated autoimmune diseases caused by excessive production of interferon-$g(g).
(FR)
L'invention concerne des gènes ainsi que des protéines mammifères, appelés facteurs inhibiteurs de la synthèse de cytokines (FISC), capables d'inhiber la synthèse de cytokines associée à des réponses d'hypersensibilité de type retardé, et lesquels, avec des antagonistes, sont utiles pour traiter des maladies associées aux déséquilibres de cytokines, telles que la leishmaniose et d'autres infections parasitaires, ainsi que certains troubles immuns parmi lesquels des troubles autoimmuns associés au CMH (complexe majeur d'hystocompatibilité) provoquées par la production excessive d'interféron-$g(g).
Latest bibliographic data on file with the International Bureau